News

NightBalance closes EUR 12.5 million Series B financing to support commercial rollout in Europe and enter the U.S. market with its innovative sleep apnea device

Date: 05/07/2016

5 July 2016, Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep apnea (OSA) technology, today announced the completion of a EUR 12.5 million Series B financing round led by INKEF Capital and Gilde Healthcare Partners. Existing investors Thuja Capital, Health Innovation Fund, and Van Herk Ventures also participated. Dirk Kersten from INKEF, and Pieter van der Meer from Gilde will join the supervisory board, which will be chaired by Jan Keltjens and further strengthened with the appointment of Geoff Waters.

The proceeds of the Series B financing allow NightBalance to intensify and expand commercial efforts for its innovative Sleep Position Trainer in Europe, and to prepare for the company’s entry into the U.S. market. NightBalance is planning for further clinical research in the U.S., guided by the leading sleep specialist Prof. Dr. David P. White from Harvard Medical School and former Chief Medical Officer for Philips Respironics. Also filing for U.S. Food and Drug Administration 510(k) clearance is being prepared.

“We are delighted to welcome INKEF and Gilde to our investor base, and to significantly strengthen our board and management with seasoned industry executives Jan Keltjens, Geoff Waters, and John Lipman” said Eline Vrijland-van Beest, founder and CEO of NightBalance. “In the EU and U.S. alone, an estimated 25 million people suffer from sleep apnea of which 80% goes undiagnosed or is not helped with current treatments; our mission is to change these lives. This financing will allow us to move full steam ahead and increase our market penetration in Europe’s billion dollar market, and -under the leadership of John Lipman who joins us from Apnicure Inc.- build the necessary infrastructure to access the U.S. market. We are committed to continue to generate solid clinical data demonstrating the benefits of the Sleep Position Trainer to support its further adoption by clinicians, patients, and payors.”

“NightBalance stands out in the emerging field of novel sleep apnea technologies with their continued commitment to generate high-quality and actionable clinical data sets underpinning the ease of use and efficacy of the Sleep Position Trainer,” said Jan Keltjens. “I look forward to working with Eline and her team as well as the Board to help navigate the company’s important next phase of growth and development.”

About Jan Keltjens

Mr. Keltjens has a strong track record in the medical device sector and more than 30 years of management experience. He is currently Chairman of the Board of JenaValve, holds a number of non-executive Board roles. Jan served as the Chief Executive Officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in August 2014), Endosense (acquired by St Jude Medical in August 2013), Surpass Medical (acquired by Stryker in August 2012, Cryocath (acquired by Medtronic in 2009) and Angiodynamics (NASDAQ – ANGO).

About Geoffrey C. Waters

Geoff Waters was President of Respironics’ International Group from 1996 until 2008 when the company was acquired by Philips Healthcare. From 1984 until 1996, Waters was at Lifecare International in roles of increasing responsibility. As President and Chief Operating Officer of Lifecare International, he played an instrumental role in preparing for the sale of Lifecare International to Respironics in 1996.

About John Lipman

John Lipman joins NightBalance from Apnicure Inc. where he was VP of Marketing and Commercial Development. Lipman has more than 20 years of experience in healthcare marketing and sales, with a focus on consumer medical devices. He has a proven track record in developing and executing strategic market entry plans for companies with new and emerging technologies.

About Prof. Dr. David P. White

David P. White, M.D. is a professor of sleep medicine at the Harvard Medical School in Boston. He is an international thought leader, lecturer and researcher specialized in the diagnosis and treatment of Obstructive Sleep Apnea. Besides several non-executive Board roles such as the Chair for the NightBalance Medical Advisory Board, he was the former Chief Medical Officer for Philips Respironics.

About INKEF Capital

INKEF is an Amsterdam, the Netherlands, based venture capital firm that is focused on the long-term collaboration and active support of innovative technology companies. INKEF was founded in 2010 by Dutch pension fund ABP and with €200 million under management it is one of the largest venture capital funds in the Netherlands. INKEF focuses on investment opportunities in Healthcare, Technology and IT/NewMedia and prefers to participate from series A round financing onwards. Dirk Kersten is a Managing Director at INKEF.

About Gilde

Gilde is a transatlantic specialist investment firm. It manages over €800 million ($910 million) in growth capital funds dedicated to innovative therapeutic and medical technology companies in Europe and the United States as well as mid-market healthcare service companies in the Benelux and Germany. Pieter van der Meer is a Managing Partner at Gilde.

About the Sleep Position Trainer

NightBalance’s Sleep Position Trainer (SPT) trains patients not to sleep on their back (supine) to prevent positional obstructive sleep apnea. Worn on the chest, the SPT constantly measures the sleep position, and gently nudges users to change position while leaving the natural sleep pattern unaffected. The SPT activates itself after 30 minutes, allowing patients to fall asleep in any position, and its smart hardware uses individually adjusted vibration strengths and patterns to assure sustained effectiveness. The SPT is prescribed by ear, nose and throat specialists or pulmonologists.

About NightBalance

NightBalance, founded in 2009 and based in Delft, the Netherlands, developed and markets the Sleep Position Trainer, a proprietary, highly advanced and easy to use device to prevent positional obstructive sleep apnea. CE-marked since 2012, the SPT is currently sold in 11 European countries. NightBalance’s wealth of clinical data supports the efficacy and ease of use of the SPT, and has demonstrated a substantial increase in patient compliance.

For more information:
Eline Vrijland-van Beest, CEO
Tel: + 31 642 24 14 11
eline@nightbalance.com

Hans Herklots (media)
Capricorn One
+41 79 598 7149
capricorn1@bluewin.ch